European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2026-03 · 26 (3) · e408-e420
DOI: 10.1016/j.clml.2025.12.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-03. Verfasst von Paula Rodríguez-Otero und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center Clínica Universidad de Navarra, CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain. Electronic address: paurodriguez@unav.es. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson.
Abstract (Originalsprache)
The global incidence of multiple myeloma (MM) continues to rise. While survival rates for newly diagnosed patients have improved substantially with the introduction of novel therapies, outcomes remain poor for those with triple-class-exposed (TCE) relapsed/refractory MM (RRMM). Recent therapeutic innovations, including chimeric antigen receptor T-cell therapy, antibody-drug conjugates, and bispecific antibodies, offer new effective options for this challenging population. Teclistamab, the first approved B-cell maturation antigen-targeted bispecific antibody, has demonstrated deep and durable responses and an acceptable safety profile in TCE RRMM. Teclistamab is now a recommended treatment from second relapse onwards in patients with TCE RRMM in the 2025 European Hematology Association-European Myeloma Network guidelines. Nevertheless, considering the novelty of this agent and its overall safety profile, there is a need for clear guidance on patient management in routine clinical practice. Here, we aim to provide a comprehensive overview of the clinical profile of teclistamab and expert recommendations on its optimal use in TCE RRMM. We focus on key aspects and considerations needed for patient selection (including special populations such as the elderly, frail individuals, those with extramedullary disease or renal impairment), as well as therapy initiation, and strategies for adverse event prevention, monitoring, and management. Ultimately, this review aims to support physicians in maximizing the therapeutic potential of teclistamab, improving outcomes for patients through tailored, evidence-based management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center Clínica Universidad de Navarra, CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain. Electronic address: paurodriguez@unav.es.
- Centre Hospitalier Universitaire de Nantes, Nantes, France.
- University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain.
- Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
- Department of Clinical Therapeutics, School of Medicine, "Alexandra" General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Förderung
- Johnson and Johnson
Zitieren
APA
Rodríguez-Otero, P., Moreau, P., Mateos, M. V., Krauth, M. T., Rasche, L., Kastritis, E., Oriol, A., Zamagni, E., Albrecht, C., Rubio-Azpeitia, E., & van de Donk, N. W. C. J. (2026). European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 26(3), e408-e420. https://doi.org/10.1016/j.clml.2025.12.003
Vancouver
Rodríguez-Otero P, Moreau P, Mateos MV, Krauth MT, Rasche L, Kastritis E, et al. European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026;26(3):e408-e420. doi:10.1016/j.clml.2025.12.003
BibTeX
@article{RodrguezOtero2026,
author = {Rodríguez-Otero, Paula and Moreau, Philippe and Mateos, Maria Victoria and Krauth, Maria Theresa and Rasche, Leo and Kastritis, Efstathios and Oriol, Albert and Zamagni, Elena and Albrecht, Claire and Rubio-Azpeitia, Eva and van de Donk, Niels W C J},
title = {European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {3},
pages = {e408--e420},
doi = {10.1016/j.clml.2025.12.003}
}
EUVIMED